Drug intelligence / Profile preview

Stravix

Development stage
Phase 2
Lead developer
Smith & Nephew
Modality
Tissue Cells → Other Cell Types → Cell Therapies
Administration
Topical, Surgical Implant
01

Overview

Stravix is a structural placental allograft product composed of human umbilical tissue, specifically the amniotic and connective layers of the umbilical cord. It is available as a cryopreserved or lyopreserved (Stravix PL) tissue graft designed for use in wound care and surgical applications. The product retains native components such as collagen, hyaluronic acid-rich extracellular matrix, cytokines, fibroblasts, growth factors, viable endogenous mesenchymal stem cells, and epithelial cells. Blood vessels are removed to reduce immunogenicity while preserving biological activity. Stravix is used as a cover or wrap for acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers, pressure injuries—as well as in surgical procedures involving tendon repair, nerve repair, bone coverage or soft tissue reinforcement. Its mechanism relies on providing a natural scaffold that supports cellular growth and tissue regeneration by maintaining the properties inherent to fresh placental tissues[2][3][4][5][7].

Brand names
Stravix
Other names
Stravix Cryopreserved Umbilical TissueStravix Tissue

Beyond the preview

Go deeper on Stravix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stravix.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call